The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Circulating calprotectin, innate inflammatory protein, was decreased under disease control during first-line chemotherapy for advanced pancreatic cancer.
 
Taro Shibuki
No Relationships to Disclose
 
Shuichi Mitsunaga
No Relationships to Disclose
 
Motoyasu Kan
No Relationships to Disclose
 
Gen Kimura
No Relationships to Disclose
 
Kumiko Umemoto
No Relationships to Disclose
 
Kazuo Watanabe
No Relationships to Disclose
 
Mitsuhito Sasaki
No Relationships to Disclose
 
Hideaki Takahashi
Honoraria - Bayer; Taiho Pharmaceutical; Torii Pharmaceutical
Research Funding - Bayer (Inst); Bristol-Myers Squibb (Inst)
 
Yusuke Hashimoto
No Relationships to Disclose
 
Hiroshi Imaoka
No Relationships to Disclose
 
Izumi Ohno
Consulting or Advisory Role - Merck Serono
Speakers' Bureau - Taiho Pharmaceutical
 
Masafumi Ikeda
Honoraria - Abbott Japan; Bayer Yakuhin; Bristol-Myers Squibb Japan; Dainippon Sumitomo Pharma; Eisai; Lilly Japan; Nobelpharma; Novartis; Otsuka; Taiho Pharmaceutical; Teijin Pharma; Yakult Honsha
Consulting or Advisory Role - Bayer Yakuhin; Daiichi Sankyo; Eisai; Kyowa Hakko Kirin; Lilly Japan; MSD; NanoCarrier; Novartis; Shire; Teijin Pharma
Research Funding - ASLAN Pharmaceuticals; AstraZeneca; Baxalta/Shire; Bayer Yakuhin; Bristol-Myers Squibb; Chugai Pharma; Eisai; Kowa; Kyowa Hakko Kirin; Lilly Japan; Merck Serono; MSD; NanoCarrier; Novartis; Ono Pharmaceutical; Taiho Pharmaceutical; Takara Bio; Yakult Pharmaceutical